Metropolis Healthcare (BOM:542650) Cash And Cash Equivalents : ₹626 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Metropolis Healthcare Cash And Cash Equivalents?

Metropolis Healthcare's quarterly cash and cash equivalents declined from Sep. 2023 (₹509.30 Mil) to Dec. 2023 (₹0.00 Mil) but then increased from Dec. 2023 (₹0.00 Mil) to Mar. 2024 (₹626.18 Mil).

Metropolis Healthcare's annual cash and cash equivalents increased from Mar. 2022 (₹659.80 Mil) to Mar. 2023 (₹688.33 Mil) but then declined from Mar. 2023 (₹688.33 Mil) to Mar. 2024 (₹626.18 Mil).

Metropolis Healthcare Cash And Cash Equivalents Historical Data

The historical data trend for Metropolis Healthcare's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Metropolis Healthcare Cash And Cash Equivalents Chart

Metropolis Healthcare Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash And Cash Equivalents

Get a 7-Day Free Trial

1,071.74

3,865.93

659.80

688.33

626.18

Metropolis Healthcare Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															688.33	-	509.30	-	626.18

Metropolis Healthcare Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Metropolis Healthcare (BOM:542650) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Metropolis Healthcare Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Metropolis Healthcare's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Metropolis Healthcare (BOM:542650) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Metropolis Healthcare Ltd (BOM:542650) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

METROPOLIS:India

Address

Hind Cycle Marg, 250-D, Udyog Bhavan, Behind Glaxo, Worli, Mumbai, MH, IND, 400 030

Website

https://www.metropolisindia.com

Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.

Metropolis Healthcare (BOM:542650) Headlines

No Headlines